Benkill CV 500mg+125mg

Tablet
Cefuroxime Axetil + Clavulanic Acid
BENHAM pharmaceuticals

Other Strength:
- Benkill 250mg
- Benkill 500mg
- Benkill CV 250mg+62.5mg

Alternative:
- Furotil Plus 500mg+125mg
- Clavurox 500mg+125mg
- Cerox CV 500mg+125mg
- Xiclav 500mg+125mg
- Claviator-CV 500mg+125mg
- Axeclav 500mg+125mg
- Axim CV 500mg+125mg
- Cefotil Plus 500mg+125mg
- Famiclav 500mg+125mg
- Turboclav 500mg+125mg
- Furoclav 500mg+125mg



Benkill CV
Presentation:
Benkill CV 250 Tablet: Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg and Diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 62.50 mg.
Benkill CV 500 Tablet: Each film coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg and Diluted Potassium Clavulanate BP equivalent to Clavulanic Acid 125 mg.

Pharmacology:
Cefuroxime has bactericidal activity against a wide range of bacteria, including beta-lactamase producing strains. The bactericidal action of Cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins. Cefuroxime has good stability to bacterial beta-lactamases. Clavulanic acid is a naturally derived beta lactamase inhibitor produced by Streptomyces clavuligerus. It has similar structure to beta lactam antibiotics but binds irreversibly to beta-lactamase enzymes and inactivates them. Clavulanic acid gives protection of Cefuroxime from degradation by beta lactamase enzymes and provides a solution for the treatment of bacterial infections caused by beta lactam resistant bacteria. Indications: Benkill CV is indicated for the treatment of the following infections caused by susceptible microorganisms:
- Pharyngitis/Tonsillitis caused by Streptococcus pyogenes
- Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis(including beta-lactamase-producing strains), or Streptococcus pyogenes
- Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae(non-beta-lactamase-producing strains only)
- Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains)
- Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase-producing strains) or Streptococcus pyogenes
- Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae.
- Uncomplicated Gonorrhea (urethral and endocervical) caused by penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, (rectal) in females, caused by non-penicillinase-producing strains of Neisseria gonorrhoeae.
- Lyme disease (erythema migrans) caused by Borrelia burgdorferi.
- Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains) & Klebsiella spp
. - Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis & Staphylococcus aureus (penicillinase and non-penicillinase producing strains) - Switch therapy (Injectable to oral)

Dosage & Administration:
Patients Indications Dosage Duration
Pharyngitis/tonsillitis 250 mg
twice daily 5-10
Acute bacterial maxillary sinusitis 250 mg
twice daily 10
Acute bacterial exacerbations 250-500 mg
of chronic bronchitis twice daily 10

Secondary bacterial infections 250-500mg
of acute bronchitis twice daily 5-10

Uncomplicated skin & 250-500mg
skin-structure infections twice daily 10

Adolescents Uncomplicated urinary tract infections 250mg
and Adults twice daily 7-10
(13 years and older)
Uncomplicated gonorrhea 1000mg single dose

Community acquired pneumonia 250-500mg
twice daily 5-10

MDR Typhoid fever 500mg
twice daily 10-14

Lyme disease 500mg
twice daily 20

Pharyngitis/tonsillitis 20 mg/kg/day
in 2 divided 5-10
dose
Acute otitis media 30mg/kg/day
in 2 divided 10
dose

Acute bacterial maxillary sinusitis 30mg/kg/day
in 2 divided 10
dose


Pediatric Patients Uncomplicated skin & 30mg/kg/day
(3 months to 12 years) skin-structure infections in 2 divided 10
dose

Community acquired pneumonia 30mg/kg/day
in 2 divided 5-10
dose

MDR Typhoid fever 30mg/kg/day 10-14
in 2 divided
dose

Uncomplicated urinary tract infection 20mg/kg/day
in 2 divided 7-10
dose

Contraindications:
Cefuroxime-Clavulanic Acid is contraindicated in patients with known allergy to cephalosporin & in patients with Pseudomembranous Colitis. Precautions: Cefuroxime-Clavulanic Acid should be given with care to patients receiving concurrent treatment with potent diuretics & who have history of Pseudomembranous Colitis. Side Effects: Generally Cefuroxime-Clavulanic Acid is well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime and Clavulanic acid combination may result in overgrowth of nonsusceptible microorganisms. Rarely (<0.2%) renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear. Drug interactions: Concomitant administration of probenecid with Cefuroxime-Clavulanic Acid increases the area under the serum concentration versus time curve by 50%. Drug that reduces gastric acidity may result in a lower bioavailability of Cefuroxime and tend to cancel the effect of postprandial absorption.

Pregnancy & Lactation:
Use in pregnancy:
While all antibiotics should be avoided in the first trimester if possible. However, Cefuroxime-Clavulanic Acid can be safely used in later pregnancy to treat urinary and other infections.
Use in lactation:
Cefuroxime-Clavulanic Acid is excreted into the breast milk in small quantities. However, the possibility of sensitizing the infant should be kept in mind.

এই পাতাটি ৩৪৬ বার দেখা হয়েছে